The planned program will include two Phase 3 trials: FASCINATE-3, evaluating patients with F2/F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

THE effect of increased intra-abdominal pressure due to ascites upon portal and systemic hemodynamics has not been directly documented although the hemodynamics of ascitic cirrhotic patients have ...

Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.

Data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at ...

Methods: We employed 16S ribosomal RNA sequencing, internal transcribed spacer sequencing, and untargeted metabolomics techniques to investigate the composition and interaction of gut bacteria, fungi, ...

The most famous long-term complication is anastomotic stricture, whereas non-cirrhotic portal hypertension secondary to cholangiointestinal anastomotic stricture is rare. Case summary: Here we report ...